BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12823591)

  • 21. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients.
    Seta T; Yokosuka O; Imazeki F; Tagawa M; Saisho H
    J Med Virol; 2000 Jan; 60(1):8-16. PubMed ID: 10568756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
    Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
    Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
    Liang WF; Yang DH; Shen YH; Xie YJ; Zhao NF
    Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance.
    Li MW; Hou W; Wo JE; Liu KZ
    J Zhejiang Univ Sci B; 2005 Jul; 6(7):664-7. PubMed ID: 15973769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
    Inoue J; Ueno Y; Wakui Y; Niitsuma H; Fukushima K; Yamagiwa Y; Shiina M; Kondo Y; Kakazu E; Tamai K; Obara N; Iwasaki T; Shimosegawa T
    J Viral Hepat; 2011 Mar; 18(3):206-15. PubMed ID: 20367795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
    Nafa S; Ahmed S; Tavan D; Pichoud C; Berby F; Stuyver L; Johnson M; Merle P; Abidi H; Trépo C; Zoulim F
    Hepatology; 2000 Nov; 32(5):1078-88. PubMed ID: 11050059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of hepatitis B virus polymerase variations resistant to lamivudine therapy.
    Zhang X; Han Y; Lu Z; Zhang D; Cai Y
    Chin Med J (Engl); 2000 May; 113(5):455-7. PubMed ID: 11776105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of peptide nucleic acid mediated polymerase chain reaction clamping (PMPC)--direct sequencing method for detecting lamivudine-resistant hepatitis B virus (HBV) variants with high sensitivity and specificity.
    Ogata N; Ichida T; Aoyagi Y; Kitajima I
    Rinsho Byori; 2003 Apr; 51(4):313-9. PubMed ID: 12747252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.
    Tan YW; Ye Y; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
    World J Gastroenterol; 2015 Feb; 21(7):2089-95. PubMed ID: 25717242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
    Mirandola S; Campagnolo D; Bortoletto G; Franceschini L; Marcolongo M; Alberti A
    J Viral Hepat; 2011 Jul; 18(7):e212-6. PubMed ID: 21692935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus.
    Chen RY; Bowden S; Desmond PV; Dean J; Locarnini SA
    J Gastroenterol Hepatol; 2003 Jun; 18(6):630-7. PubMed ID: 12753143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
    Chang UI; Lee YC; Wie SH; Jang JW; Bae SH; Choi JY; Yang JM; Yoon SK; Sun HS
    J Med Virol; 2007 Jul; 79(7):902-10. PubMed ID: 17516533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.
    Westland CE; Yang H; Delaney WE; Wulfsohn M; Lama N; Gibbs CS; Miller MD; Fry J; Brosgart CL; Schiff ER; Xiong S
    J Viral Hepat; 2005 Jan; 12(1):67-73. PubMed ID: 15655050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.
    Tatulli I; Francavilla R; Rizzo GL; Vinciguerra V; Ierardi E; Amoruso A; Panella C; Francavilla A
    J Hepatol; 2001 Dec; 35(6):805-10. PubMed ID: 11738109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mutations of HBV polymerase gene sequence in lamivudine-resistant chronic hepatitis B patients].
    Wang C; Sun J; Chen JJ; Wang ZH; Hou JL
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):729-30. PubMed ID: 18504191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy.
    Niesters HGM; DE Man RA; Pas SD; Fries E; Osterhaus ADME
    J Med Microbiol; 2002 Aug; 51(8):695-699. PubMed ID: 12171302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
    Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
    J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
    Audsley J; Arrifin N; Yuen LK; Ayres A; Crowe SM; Bartholomeusz A; Locarnini SA; Mijch A; Lewin SR; Sasadeusz J
    HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.